1. Antibody-drug Conjugate/ADC Related Protein Tyrosine Kinase/RTK Cell Cycle/DNA Damage Metabolic Enzyme/Protease Vitamin D Related/Nuclear Receptor
  2. ADC Antibody RET PERK ROR
  3. Cofetuzumab

Cofetuzumab  (Synonyms: PF-06523435; hu24)

Cat. No.: HY-P99828 Pureté: 99.31%
Technical Support

Cofetuzumab (PF-06523435) is a humanized IgG1-κ monoclonal antibody targeting PTK7. The expression system of Cofetuzumab is typically CHO (Chinese hamster ovary) cells. Cofetuzumab downregulates PTK7 expression, modulates its downstream signaling pathways, and inhibits tumor sphere formation of ovarian cancer cells. Cofetuzumab can be used to synthesize the ADC molecule Cofetuzumab pelidotin (HY-P99829). Cofetuzumab is applicable to the research of tumors such as ovarian cancer.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

CAS No. : 1869928-62-0

Size Prix Stock Quantité
Échantillon gratuit (100 μg)   Appliquer maintenant  
1 mg En stock
5 mg En stock
10 mg En stock
25 mg En stock
50 mg En stock
100 mg   Obtenir un devis  
200 mg   Obtenir un devis  

* Veuillez sélectionner la quantité avant d'ajouter des articles.

This product is a controlled substance and not for sale in your territory.

Top Publications Citing Use of Products

Voir tous les produits spécifiques à Isoform ROR:

  • Activité biologique

  • Pureté et documentation

  • Références

  • Avis client

Description

Cofetuzumab (PF-06523435) is a humanized IgG1-κ monoclonal antibody targeting PTK7. The expression system of Cofetuzumab is typically CHO (Chinese hamster ovary) cells. Cofetuzumab downregulates PTK7 expression, modulates its downstream signaling pathways, and inhibits tumor sphere formation of ovarian cancer cells. Cofetuzumab can be used to synthesize the ADC molecule Cofetuzumab pelidotin (HY-P99829). Cofetuzumab is applicable to the research of tumors such as ovarian cancer[1].

Isotype

Human IgG1 kappa

Recommend Isotype Controls
Species Reactivity

Human

IC50 & Target

PTK7/CCK4

In Vitro

Cofetuzumab (10 μg/mL; 48 h) upregulates pERK1/2 in FIMM-PDC1-PDC3, and simultaneously upregulates ROR1 expression in FIMM-PDC3 with high PTK7 expression[1].
Cofetuzumab (10 μg/mL; 48 h) downregulates the expression level of SNCG protein in Kuramochi cells and FIMM-PDC1 cells[1].
Cofetuzumab (20 μg/mL; 5 days) inhibits tumor sphere formation and induces more dispersed structures in JHOS2, Kuramochi, FIMM-PDC3 and FIMM-PDC7 cells[1].
Cofetuzumab (10 μg/mL; 24 h) exerts synergistic cytotoxicity with Prexasertib (HY-18174) and Paclitaxel (HY-B0015) in FIMM-PDC3 cells[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line: Kuramochi (high-grade serous ovarian cancer cell line), FIMM-PDC1 (high-grade serous ovarian cancer patient-derived cell culture)
Concentration: 10 μg/mL
Incubation Time: 48 h
Result: Downregulated synuclein-γ (SNCG) protein levels in both cell models.
Gene ID

5754  [NCBI]

Accession

Q13308-1

Application

ELISA, FACS, Functional assay

Conjugated

Unconjugated

Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.

Masse moléculaire

146.7 kDa

CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Cofetuzumab]

Livraison

Shipping with dry ice.

Formulation

Please refer to the lot-specific COA for specific buffer information.

Stockage

Please store the product under the recommended conditions in the Certificate of Analysis.

Format
  • Human IgG1 kappa
Biological Activity
  • Immobilized Human PTK7/CCK4, Fc Tag can bind Cofetuzumab. The EC50 for this effect is 21.74 ng/mL.
  • Flow Cytometry analysis of Hela cells labelling PTK7/CCK4 (red) with Cofetuzumab (anti-PTK7/CCK4) (HY-P99828). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody.
Pureté et documentation

Purity: 99.31%

Références
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Calculateur de molarité

  • Calculateur de dilution

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Vos produits récemment consultés:

Demande en ligne

Your information is safe with us. * Required Fields.

Nom du produit

 

Requested Quantity *

Nom du demandeur *

 

Civilité

Adresse e-mail *

 

Numéro de téléphone *

Department

 

Nom de l'organisation *

City

État

Country or Region *

     

Remarques

Bulk Inquiry

Inquiry Information

Nom du produit:
Cofetuzumab
Cat. No.:
HY-P99828
Quantité:
MCE Japan Authorized Agent: